AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics focused on exploring cancer drug combinations, according to comments from AstraZeneca CEO Pascal Soriot. The deal represents a roughly 12% stake in Summit and does not constitute an acquisition or licensing agreement, allowing Summit to retain full control and commercial rights to its lead compound.
The centerpiece of the partnership is ivonescimab, a first-in-class bispecific antibody that simultaneously targets two pathways involved in cancer progression. The drug blocks PD-1, which normally suppresses immune cell activity, and VEGF, which promotes tumor blood vessel formation. By inhibiting both mechanisms, the therapy aims to activate the immune system against cancer cells while cutting off the blood supply tumors require for growth. Clinical trials demonstrated that ivonescimab outperformed Merck’s Keytruda, a widely-used immunotherapy and historically one of the world’s highest-grossing medications, in treating advanced non-small cell lung cancer.
Soriot characterized ivonescimab as representative of a next generation of cancer treatments beyond first-generation PD-1 inhibitors. He highlighted particular potential in combining the drug with AstraZeneca’s antibody-drug conjugate portfolio for treating multiple tumor types more effectively than existing therapies. The investment reflects broader pharmaceutical industry interest in bispecific antibodies and similar mechanisms of action.
Separately, AstraZeneca inaugurated a new research and development facility in Cambridge, Massachusetts spanning 570,000 square feet with over $1 billion in investment. The facility will pursue drug development across obesity, breast cancer, COPD and rare diseases. The company indicated approximately 20% of the facility’s investment targets robotics and artificial intelligence systems designed to accelerate drug discovery and reduce development costs while maintaining quality standards.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI